CEO Kathryn Haviland was paid $13,477,004 in fiscal year 2024, ↑ up 109.5% from fiscal year 2023, the 76th percentile of its disclosed peer group (SEC filing 0001558370-25-005415 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$13,477,004 ↑ Kathryn Haviland total, FY2024 | 76th CEO pay percentile vs peers | 35:1 CEO-to-median pay ratio | 95.93% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Kathryn Haviland | $821,363 | $0 | $7,472,480 | $4,315,144 | $854,217 | $0 | $13,800 | $13,477,004 |
| President and Chief Executive Officer | ||||||||
| Christina Rossi | 668,410 | 0 | 3,700,218 | 1,618,179 | 541,412 | 0 | 13,800 | 6,542,019 |
| Chief Operating Officer | ||||||||
| Fouad Namouni | 671,809 | 0 | 2,649,360 | 1,618,179 | 544,165 | 0 | 13,800 | 5,497,313 |
| President, Research and Development | ||||||||
| Percy Carter | 619,233 | 0 | 2,687,050 | 1,348,483 | 417,982 | 0 | 59,715 | 5,132,463 |
| Chief Scientific Officer | ||||||||
| Michael Landsittel | 573,593 | 0 | 1,868,200 | 1,348,483 | 387,175 | 0 | 13,800 | 4,191,251 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Kathryn Haviland | $13,477,004 | $6,432,012 | $6,217,694 | ↑ +7,044,992 |
| Christina Rossi | 6,542,019 | 2,806,209 | 2,769,000 | ↑ +3,735,810 |
| Fouad Namouni | 5,497,313 | 2,801,778 | 2,810,182 | ↑ +2,695,535 |
| Percy Carter | 5,132,463 | 2,299,827 | 1,992,743 | ↑ +2,832,636 |
| Michael Landsittel | 4,191,251 | 2,194,830 | 2,363,511 | ↑ +1,996,421 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Blueprint Medicines's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper BPMC reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name BPMC as a peer is temporarily unavailable — recheck shortly.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2024 total |
|---|---|---|
| Percy Carter | Chief Scientific Officer | $5,132,463 |
| Fouad Namouni | President | $5,497,313 |
| Christina Rossi | COO | $6,542,019 |
| Kathryn Haviland | CEO | $13,477,004 |
| Michael Landsittel | CFO | $4,191,251 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2024 total |
|---|---|---|
| Alexis Borisy | Independent Director | $549,690 |
| Daniella Beckman | Independent Director | $574,690 |
| Habib Dable | Independent Director | $564,990 |
| Jeffrey W. Albers | Chair of the Board | $586,190 |
| John Tsai | Independent Director | $549,690 |
| Lonnel Coats | Independent Director | $572,590 |
| Lynn Seely | Lead Independent Director | $606,190 |
| Mark Goldberg | Independent Director | $586,690 |
| Nicholas Lydon | Independent Director | $569,690 |
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Christina Rossi | CHIEF OPERATING OFFICER | 2025-05-05 | D | 607 | $101 | $61,289 | Common | Form 4 ↗ |
| Ariel Hurley | PRINCIPAL ACCOUNTING OFFICER | 2025-05-05 | A | 2,752 | 54 | 148,966 | Common | Form 4 ↗ |
| Ariel Hurley | PRINCIPAL ACCOUNTING OFFICER | 2025-05-05 | D | 2,752 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ariel Hurley | PRINCIPAL ACCOUNTING OFFICER | 2025-05-05 | D | 100 | 105 | 10,478 | Common | Form 4 ↗ |
| Ariel Hurley | PRINCIPAL ACCOUNTING OFFICER | 2025-05-05 | D | 1,252 | 103 | 128,343 | Common | Form 4 ↗ |
| Christina Rossi | CHIEF OPERATING OFFICER | 2025-05-05 | D | 180 | 103 | 18,508 | Common | Form 4 ↗ |
| Christina Rossi | CHIEF OPERATING OFFICER | 2025-05-05 | D | 144 | 104 | 14,913 | Common | Form 4 ↗ |
| Christina Rossi | CHIEF OPERATING OFFICER | 2025-05-05 | D | 1,343 | 102 | 136,677 | Common | Form 4 ↗ |
| Christina Rossi | CHIEF OPERATING OFFICER | 2025-05-19 | D | 804 | 100 | 80,513 | Common | Form 4 ↗ |
| Christina Rossi | CHIEF OPERATING OFFICER | 2025-05-19 | D | 57 | 102 | 5,798 | Common | Form 4 ↗ |
| Christina Rossi | CHIEF OPERATING OFFICER | 2025-05-19 | D | 1,413 | 101 | 142,247 | Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-05-27 | D | 4,350 | 101 | 439,437 | Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-05-27 | D | 650 | 102 | 66,255 | Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-05-27 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-05-27 | A | 5,000 | 36 | 180,250 | Common | Form 4 ↗ |
| Percy Carter | CHIEF SCIENTIFIC OFFICER | 2025-06-03 | D | 2,418 | 128 | 309,214 | Common | Form 4 ↗ |
| Percy Carter | CHIEF SCIENTIFIC OFFICER | 2025-06-03 | D | 241 | 128 | 30,819 | Common | Form 4 ↗ |
| Alexis Borisy | Director | 2025-06-18 | A | 3,902 | 128 | 499,924 | Common | Form 4 ↗ |
| Mark Goldberg | Director | 2025-06-18 | A | 3,902 | 128 | 499,924 | Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-06-18 | A | 3,902 | 12,812 | 49,992,424 | Common | Form 4 ↗ |
| John Tsai | Director | 2025-06-18 | A | 3,902 | 128 | 499,924 | Common | Form 4 ↗ |
| Daniella Beckman | Director | 2025-06-18 | A | 3,902 | 128 | 499,924 | Common | Form 4 ↗ |
| Habib Dable | Director | 2025-06-18 | A | 3,902 | 128 | 499,924 | Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-06-18 | A | 3,902 | 128 | 499,924 | Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-06-18 | A | 3,902 | 128 | 499,924 | Common | Form 4 ↗ |
| Christina Rossi | CHIEF OPERATING OFFICER | 2025-07-03 | D | 1,172 | 128 | 150,309 | Common | Form 4 ↗ |
| Percy Carter | CHIEF SCIENTIFIC OFFICER | 2025-07-03 | D | 1,051 | 128 | 134,791 | Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | D | 43,175 | — | — | Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | A | 21,353 | — | — | Common | Form 4 ↗ |
| Fouad Namouni | PRESIDENT, R & D | 2025-07-17 | D | 65,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Goldberg | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Goldberg | Director | 2025-07-17 | D | 7,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Goldberg | Director | 2025-07-17 | D | 10,909 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Goldberg | Director | 2025-07-17 | D | 18,254 | — | — | Common | Form 4 ↗ |
| Mark Goldberg | Director | 2025-07-17 | D | 3,902 | — | — | Common | Form 4 ↗ |
| Alexis Borisy | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-17 | D | 26,400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-17 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 4,570 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 10,909 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 10,909 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 21,818 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 5,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-07-17 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Debra Durso-Bumpus | Chief People Officer | 2025-07-17 | D | 22,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-07-17 | D | 80,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-07-17 | D | 144,755 | — | — | Common | Form 4 ↗ |
| Daniella Beckman | Director | 2025-07-17 | D | 7,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Debra Durso-Bumpus | Chief People Officer | 2025-07-17 | A | 21,353 | — | — | Common | Form 4 ↗ |
| Daniella Beckman | Director | 2025-07-17 | D | 10,842 | — | — | Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 39,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Goldberg | Director | 2025-07-17 | D | 4,570 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 591 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-17 | D | 20,628 | — | — | Common | Form 4 ↗ |
| Percy Carter | Chief Scientific Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 4,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| L. Becker Hewes | Chief Medical Officer | 2025-07-17 | D | 13,490 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-07-17 | D | 4,875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | D | 9,494 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Habib Dable | Director | 2025-07-17 | D | 8,742 | — | — | Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | D | 26,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 80,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 2 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 70,729 | — | — | Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 224,410 | — | — | Common | Form 4 ↗ |
| Percy Carter | Chief Scientific Officer | 2025-07-17 | D | 39,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Percy Carter | Chief Scientific Officer | 2025-07-17 | D | 17,894 | — | — | Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 7,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| L. Becker Hewes | Chief Medical Officer | 2025-07-17 | D | 19,271 | — | — | Derivative, Class A Common | Form 4 ↗ |
| L. Becker Hewes | Chief Medical Officer | 2025-07-17 | D | 1,607 | — | — | Common | Form 4 ↗ |
| L. Becker Hewes | Chief Medical Officer | 2025-07-17 | A | 21,353 | — | — | Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-07-17 | D | 3,188 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-07-17 | D | 11,818 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | D | 7,007 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | D | 6,375 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | D | 2,751 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | D | 12,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | D | 2,250 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | D | 3,378 | — | — | Common | Form 4 ↗ |
| Habib Dable | Director | 2025-07-17 | D | 3,902 | — | — | Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | D | 10,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | D | 51,102 | — | — | Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | D | 10,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Philina Lee | Chief Commercial Officer | 2025-07-17 | D | 20,669 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Debra Durso-Bumpus | Chief People Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Debra Durso-Bumpus | Chief People Officer | 2025-07-17 | D | 21,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Debra Durso-Bumpus | Chief People Officer | 2025-07-17 | D | 15,367 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Debra Durso-Bumpus | Chief People Officer | 2025-07-17 | D | 51,103 | — | — | Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 26,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 28,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 39,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 51,103 | — | — | Common | Form 4 ↗ |
| Daniella Beckman | Director | 2025-07-17 | D | 4,570 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Goldberg | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| L. Becker Hewes | Chief Medical Officer | 2025-07-17 | D | 9,115 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | D | 26,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| L. Becker Hewes | Chief Medical Officer | 2025-07-17 | D | 50,165 | — | — | Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | D | 5,750 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | D | 11,399 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | D | 16,146 | — | — | Common | Form 4 ↗ |
| Habib Dable | Director | 2025-07-17 | D | 4,570 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Habib Dable | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | D | 22,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fouad Namouni | PRESIDENT, R & D | 2025-07-17 | D | 31,956 | — | — | Common | Form 4 ↗ |
| Fouad Namouni | PRESIDENT, R & D | 2025-07-17 | D | 83,281 | — | — | Common | Form 4 ↗ |
| Mark Goldberg | Director | 2025-07-17 | D | 4,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Goldberg | Director | 2025-07-17 | D | 4,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Goldberg | Director | 2025-07-17 | D | 4,875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexis Borisy | Director | 2025-07-17 | D | 4,570 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexis Borisy | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexis Borisy | Director | 2025-07-17 | D | 4,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexis Borisy | Director | 2025-07-17 | D | 4,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexis Borisy | Director | 2025-07-17 | D | 7,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexis Borisy | Director | 2025-07-17 | D | 74,160 | — | — | Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 70,400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 80,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 80,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 26,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 28,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | D | 32,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-17 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-17 | D | 80,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-17 | D | 82,374 | — | — | Common | Form 4 ↗ |
| Percy Carter | Chief Scientific Officer | 2025-07-17 | D | 22,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Percy Carter | Chief Scientific Officer | 2025-07-17 | D | 17,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Percy Carter | Chief Scientific Officer | 2025-07-17 | D | 56,614 | — | — | Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 4,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 13,254 | — | — | Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 3,902 | — | — | Common | Form 4 ↗ |
| L. Becker Hewes | Chief Medical Officer | 2025-07-17 | D | 22,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| L. Becker Hewes | Chief Medical Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| L. Becker Hewes | Chief Medical Officer | 2025-07-17 | D | 26,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-07-17 | D | 110,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-07-17 | D | 170,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-07-17 | D | 92,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Philina Lee | Chief Commercial Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Philina Lee | Chief Commercial Officer | 2025-07-17 | D | 6,928 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Philina Lee | Chief Commercial Officer | 2025-07-17 | D | 13,184 | — | — | Common | Form 4 ↗ |
| Philina Lee | Chief Commercial Officer | 2025-07-17 | D | 50,165 | — | — | Common | Form 4 ↗ |
| Debra Durso-Bumpus | Chief People Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Debra Durso-Bumpus | Chief People Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Debra Durso-Bumpus | Chief People Officer | 2025-07-17 | D | 26,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Debra Durso-Bumpus | Chief People Officer | 2025-07-17 | D | 30,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Debra Durso-Bumpus | Chief People Officer | 2025-07-17 | D | 19,856 | — | — | Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 22,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 29,900 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 55,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | D | 37,092 | — | — | Common | Form 4 ↗ |
| Fouad Namouni | PRESIDENT, R & D | 2025-07-17 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-17 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-17 | D | 26,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-17 | D | 28,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-17 | D | 6,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-07-17 | D | 4,570 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-07-17 | D | 10,909 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-07-17 | D | 10,909 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-07-17 | D | 6,144 | — | — | Common | Form 4 ↗ |
| Percy Carter | Chief Scientific Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Percy Carter | Chief Scientific Officer | 2025-07-17 | A | 21,353 | — | — | Common | Form 4 ↗ |
| John Tsai | Director | 2025-07-17 | D | 4,570 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Tsai | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Tsai | Director | 2025-07-17 | D | 7,950 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Tsai | Director | 2025-07-17 | D | 8,742 | — | — | Common | Form 4 ↗ |
| Daniella Beckman | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniella Beckman | Director | 2025-07-17 | D | 5,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniella Beckman | Director | 2025-07-17 | D | 3,902 | — | — | Common | Form 4 ↗ |
| Habib Dable | Director | 2025-07-17 | D | 7,950 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fouad Namouni | PRESIDENT, R & D | 2025-07-17 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fouad Namouni | PRESIDENT, R & D | 2025-07-17 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fouad Namouni | PRESIDENT, R & D | 2025-07-17 | A | 39,456 | — | — | Common | Form 4 ↗ |
| Fouad Namouni | PRESIDENT, R & D | 2025-07-17 | D | 26,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Fouad Namouni | PRESIDENT, R & D | 2025-07-17 | D | 26,400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexis Borisy | Director | 2025-07-17 | D | 4,875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alexis Borisy | Director | 2025-07-17 | D | 3,902 | — | — | Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-07-17 | D | 4,570 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-07-17 | D | 90,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey W. Albers | Director | 2025-07-17 | D | 5,777 | — | — | Common | Form 4 ↗ |
| John Tsai | Director | 2025-07-17 | D | 3,902 | — | — | Common | Form 4 ↗ |
| Michael Landsittel | Chief Financial Officer | 2025-07-17 | D | 19,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lonnel Coats | Director | 2025-07-17 | D | 4,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lynn Seely | Director | 2025-07-17 | D | 4,875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Philina Lee | Chief Commercial Officer | 2025-07-17 | D | 22,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Philina Lee | Chief Commercial Officer | 2025-07-17 | D | 8,650 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ariel Hurley | Principal Accounting Officer | 2025-07-17 | A | 2,460 | — | — | Common | Form 4 ↗ |
| Philina Lee | Chief Commercial Officer | 2025-07-17 | A | 21,353 | — | — | Common | Form 4 ↗ |
| Kathryn Haviland | Director | 2025-07-17 | A | 129,210 | — | — | Common | Form 4 ↗ |
| Christina Rossi | Chief Operating Officer | 2025-07-17 | A | 39,456 | — | — | Common | Form 4 ↗ |
| Tracey L. McCain | EVP & Chief Legal Officer | 2025-07-17 | A | 21,353 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Michael Landsittel | RSU | 2024-03-01 | — | — | 12,500 | — | $1,189,000 |
| Kathryn Haviland | PSU | 2024-03-01 | 13,500 | 27,000 | — | 54,000 | 3,667,680 |
| Michael Landsittel | PSU | 2024-03-01 | 2,500 | 5,000 | — | 10,000 | 679,200 |
| Fouad Namouni | PSU | 2024-03-01 | 4,500 | 9,000 | — | 18,000 | 1,222,560 |
| Percy Carter | PSU | 2024-03-01 | 2,500 | 5,000 | — | 10,000 | 679,200 |
| Christina Rossi | RSU | 2024-07-01 | — | — | 9,625 | — | 1,050,858 |
| Christina Rossi | PSU | 2024-03-01 | 4,500 | 9,000 | — | 18,000 | 1,222,560 |
| Fouad Namouni | OPTION | 2024-03-01 | — | — | 30,000 | — | 1,618,179 |
| Percy Carter | OPTION | 2024-03-01 | — | — | 25,000 | — | 1,348,483 |
| Percy Carter | RSU | 2024-07-01 | — | — | 7,500 | — | 818,850 |
| Kathryn Haviland | RSU | 2024-03-01 | — | — | 40,000 | — | 3,804,800 |
| Christina Rossi | RSU | 2024-03-01 | — | — | 15,000 | — | 1,426,800 |
| Kathryn Haviland | OPTION | 2024-03-01 | — | — | 80,000 | — | 4,315,144 |
| Percy Carter | RSU | 2024-03-01 | — | — | 12,500 | — | 1,189,000 |
| Michael Landsittel | OPTION | 2024-03-01 | — | — | 25,000 | — | 1,348,483 |
| Fouad Namouni | RSU | 2024-03-01 | — | — | 15,000 | — | 1,426,800 |
| Christina Rossi | OPTION | 2024-03-01 | — | — | 30,000 | — | 1,618,179 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Michael Landsittel | $1,189,000 | $679,200 | $1,348,483 | 21.1% |
| Kathryn Haviland | 3,804,800 | 3,667,680 | 4,315,144 | 31.1% |
| Fouad Namouni | 1,426,800 | 1,222,560 | 1,618,179 | 28.6% |
| Percy Carter | 2,007,850 | 679,200 | 1,348,483 | 16.8% |
| Christina Rossi | 2,477,658 | 1,222,560 | 1,618,179 | 23.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Kathryn Haviland | PSU | 27,000 | — | $2,673,092 |
| Percy Carter | PSU | 5,000 | — | 495,017 |
| Kathryn Haviland | PSU | 20,700 | — | 3,206,667 |
| Kathryn Haviland | RSU | 20,000 | — | 1,744,400 |
| Christina Rossi | Option | 1,633 | 100.13 | — |
| Kathryn Haviland | RSU | 40,000 | — | 3,488,800 |
| Kathryn Haviland | RSU | 30,000 | — | 2,616,600 |
| Christina Rossi | RSU | 15,000 | — | 1,308,300 |
| Fouad Namouni | RSU | 15,000 | — | 1,308,300 |
| Michael Landsittel | RSU | 12,500 | — | 1,090,250 |
| Percy Carter | RSU | 12,500 | — | 1,090,250 |
| Christina Rossi | RSU | 11,250 | — | 981,225 |
| Fouad Namouni | RSU | 11,250 | — | 981,225 |
| Christina Rossi | PSU | 9,000 | — | 891,031 |
| Fouad Namouni | PSU | 9,000 | — | 891,031 |
| Christina Rossi | RSU | 9,625 | — | 839,493 |
| Christina Rossi | PSU | 5,400 | — | 836,522 |
| Michael Landsittel | Option | 7,813 | 61.31 | — |
| Christina Rossi | Option | 16,875 | 43.15 | — |
| Fouad Namouni | PSU | 5,400 | — | 836,522 |
| Percy Carter | RSU | 4,374 | — | 381,500 |
| Michael Landsittel | RSU | 9,375 | — | 817,688 |
| Percy Carter | RSU | 9,375 | — | 817,688 |
| Kathryn Haviland | Option | 1,633 | 100.13 | — |
| Christina Rossi | RSU | 7,500 | — | 654,150 |
| Christina Rossi | Option | 24,375 | 95.12 | — |
| Fouad Namouni | RSU | 7,500 | — | 654,150 |
| Percy Carter | RSU | 7,500 | — | 645,150 |
| Michael Landsittel | RSU | 6,250 | — | 545,125 |
| Michael Landsittel | PSU | 5,000 | — | 495,017 |
| Christina Rossi | RSU | 3,265 | — | 284,773 |
| Percy Carter | RSU | 5,460 | — | 476,221 |
| Michael Landsittel | PSU | 2,700 | — | 418,261 |
| Percy Carter | PSU | 2,700 | — | 418,261 |
| Kathryn Haviland | RSU | 3,265 | — | 284,773 |
| Kathryn Haviland | Option | 65,000 | 95.12 | — |
| Percy Carter | Option | 14,063 | 43.15 | — |
| Michael Landsittel | RSU | 3,265 | — | 284,773 |
| Fouad Namouni | RSU | 3,265 | — | 284,773 |
| Michael Landsittel | Option | 20,313 | 95.12 | — |
| Kathryn Haviland | Option | 25,000 | 61.31 | — |
| Kathryn Haviland | Option | 45,000 | 43.15 | — |
| Michael Landsittel | Option | 1,633 | 100.13 | — |
| Michael Landsittel | Option | 14,063 | 43.15 | — |
| Christina Rossi | Option | 9,375 | 61.31 | — |
| Fouad Namouni | Option | 1,633 | 100.13 | — |
| Fouad Namouni | Option | 9,375 | 61.31 | — |
| Fouad Namouni | Option | 16,875 | 43.15 | — |
| Fouad Namouni | Option | 24,375 | 95.12 | — |
| Percy Carter | Option | 4,900 | 89.16 | — |
| Percy Carter | Option | 5,469 | 61.31 | — |
| Percy Carter | Option | 20,313 | 95.12 | — |
The compensation program is designed to promote company performance and reward value creation for stockholders by attracting, engaging, and retaining highly skilled executive talent. It aligns executives' interests with stockholders through long-term incentives linked to stock price performance and provides incentives that motivate the achievement of performance goals directly tied to business objectives and stockholder value.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-06-18 | 57,714,069 | 2,450,825 | 25,744 | 95.93% | Passed |
| 2024 | 2024-04-25 | 56,844,879 | 1,345,313 | 84,037 | 97.69% | Passed |
| 2023 | 2023-06-21 | 54,299,704 | 1,010,255 | 43,914 | 98.17% | Passed |
| 2022 | 2022-06-21 | 53,277,135 | 916,091 | 26,152 | 98.31% | Passed |
| 2021 | 2021-06-02 | 51,256,830 | 1,208,065 | 10,839 | 97.7% | Passed |
| 2020 | 2020-06-23 | 46,685,705 | 963,650 | 16,055 | 97.98% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-06-18 | 95.93%a |
| 2024 | 2024-04-25 | 97.69%b |
| 2023 | 2023-06-21 | 98.17%c |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of this proposal.”.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 35 : 1 |
|---|---|
| CEO total compensation | $13,477,004 |
| Median employee compensation | $389,871 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Lynn SeelyIndependent · Lead Independent Director · Compensation (Chair) · Nominating/Governance | $106,500 | $237,966 | $261,724 | — | — | $606,190 |
| Mark GoldbergIndependent · Audit · Compensation | 72,000 | 237,966 | 261,724 | — | 15,000 | 586,690 |
| Jeffrey W. AlbersNot independent · Board Chair | 86,500 | 237,966 | 261,724 | — | — | 586,190 |
| Daniella BeckmanIndependent · Audit (Chair) | 75,000 | 237,966 | 261,724 | — | — | 574,690 |
| Lonnel CoatsIndependent · Audit · Nominating/Governance (Chair) | 72,900 | 237,966 | 261,724 | — | — | 572,590 |
| Nicholas LydonIndependent · Not standing for re-election | 50,000 | 237,966 | 261,724 | — | 20,000 | 569,690 |
| Habib DableIndependent · Compensation · Nominating/Governance | 65,300 | 237,966 | 261,724 | — | — | 564,990 |
| John TsaiIndependent | 50,000 | 237,966 | 261,724 | — | — | 549,690 |
| Alexis BorisyIndependent | 50,000 | 237,966 | 261,724 | — | — | 549,690 |
| Kathryn HavilandEmployee director · Partial-year service | — | — | — | — | — | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 13,000 |
| Stock ownership guideline | All of our directors are in compliance with our current stock ownership guidelines. See “Other Compensation Policies and Practices – Stock Ownership Guidelines” for more information. |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $628,200 |
| Equity awards (grant-date value) | $2,141,694 |
| All other compensation | $35,000 |
| Total cost of the board | $2,804,894 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Blueprint Medicines names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Blueprint Medicines.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis, Inc. | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | PTC Therapeutic | 2025 | Matthew Klein | 958,500 | 16,593,800 | 4,399,760 | 1,294,000 | 23,266,326 |
| 3 | Halozyme Therapeutics, Inc. | 2025 | Helen Torley | 1,000,000 | 19,350,145 | 1,650,014 | 1,147,500 | 23,166,223 |
| 4 | United Therapeutics, Inc. | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 5 | Blueprint Medicines | 2024 | Kathryn Haviland | 821,363 | 7,472,480 | 4,315,144 | 854,217 | 13,477,004 |
| 6 | Neurocrine Biosciences, Inc. | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 7 | Ionis Pharmaceuticals, Inc. | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 8 | BioCryst Pharmaceuticals, Inc. | 2025 | Jon Stonehouse | 728,466 | 0 | 11,132,458 | 1,052,633 | 12,951,082 |
| 9 | Mirati Therapeutics, Inc. | 2022 | David Meek | 749,423 | 6,043,885 | 4,233,427 | 438,985 | 11,937,371 |
| 10 | Ultragenyx Pharmaceutical Inc. | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 11 | Apellis Pharmaceuticals, Inc. | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 12 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 13 | ACADIA Pharmaceuticals Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 14 | Alkermes, Inc. | 2025 | Richard Pops | 1,250,769 | 0 | 5,020,812 | 1,626,000 | 7,915,081 |
| 15 | Sarepta Therapeutics, Inc. | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
| 16 | CRISPR Therapeutics AG | 2025 | Samarth Kulkarni | 768,622 | 3,474,900 | 2,768,862 | 659,093 | 7,678,477 |
| 17 | Deciphera Pharmaceuticals, Inc. | 2023 | Steven Hoerter | 738,200 | 1,935,000 | 2,837,100 | 487,212 | 6,010,712 |
| 18 | Agios Pharmaceuticals, Inc. | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Blueprint Medicines | 130% | RSU 37 · Options 32 · PSU 31 | Yes — Relative Total Stockholder Return (rTSR) | Aon |
| ACADIA Pharmaceuticals Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Agios Pharmaceuticals, Inc. | 100% | Option 40 · PSU 40 · RSU 20 | No | Aon |
| Alkermes, Inc. | 130% | PRSU 53 · RSU 24 · Option 23 | Yes — Relative Total Shareholder Return (TSR) | Alpine Rewards LLC |
| Amicus Therapeutics, Inc. | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Apellis Pharmaceuticals, Inc. | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| BioCryst Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| CRISPR Therapeutics AG | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Deciphera Pharmaceuticals, Inc. | 110% | Option 50 · PSU 50 · RSU 25 | No | Pearl Meyer & Partners, LLC |
| Exelixis, Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Halozyme Therapeutics, Inc. | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Ionis Pharmaceuticals, Inc. | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Mirati Therapeutics, Inc. | not disclosed | Option 50 · RSU 50 | not disclosed | Aon Human Capital Solutions and Alpine Rewards |
| Neurocrine Biosciences, Inc. | 105% | Options 50 · PSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| PTC Therapeutic | not disclosed | Option 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | Frederic W. Cook & Co., Inc. |
| Sarepta Therapeutics, Inc. | 100% | PSU 50 · Option 25 · RSU 25 | No | FW Cook |
| Ultragenyx Pharmaceutical Inc. | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
| United Therapeutics, Inc. | 221% | PSO 50 · PSU 50 | No | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Kathryn Haviland | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “2024 Summary Compensation Table” · page 52. As printed: 13,477,004. Filing ↗machine: span 1101152–1101162 |
| 2 | Section 01, Christina Rossi | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “2024 Summary Compensation Table” · page 52. As printed: 6,542,019. Filing ↗machine: span 1130903–1130912 |
| 3 | Section 01, Fouad Namouni | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “2024 Summary Compensation Table” · page 52. As printed: 5,497,313. Filing ↗machine: span 1145726–1145735 |
| 4 | Section 01, Percy Carter | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “2024 Summary Compensation Table” · page 52. As printed: 5,132,463. Filing ↗machine: span 1160439–1160448 |
| 5 | Section 01, Michael Landsittel | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “2024 Summary Compensation Table” · page 52. As printed: 4,191,251. Filing ↗machine: span 1116074–1116083 |
| 6 | Section 03, Michael Landsittel RSU | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r17 · c15 · span 1269673–1269682 |
| 7 | Section 03, Kathryn Haviland PSU | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r11 · c15 · span 1237576–1237585 |
| 8 | Section 03, Michael Landsittel PSU | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r16 · c15 · span 1264378–1264385 |
| 9 | Section 03, Fouad Namouni PSU | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r27 · c15 · span 1323347–1323356 |
| 10 | Section 03, Percy Carter PSU | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r32 · c15 · span 1350207–1350214 |
| 11 | Section 03, Christina Rossi RSU | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r24 · c15 · span 1307084–1307093 |
| 12 | Section 03, Christina Rossi PSU | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r21 · c15 · span 1291194–1291203 |
| 13 | Section 03, Fouad Namouni OPTION | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t150 · r14 · c8 · span 1143581–1143590 |
| 14 | Section 03, Percy Carter OPTION | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t150 · r17 · c8 · span 1158294–1158303 |
| 15 | Section 03, Percy Carter RSU | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r35 · c15 · span 1366005–1366012 |
| 16 | Section 03, Kathryn Haviland RSU | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r12 · c15 · span 1242873–1242882 |
| 17 | Section 03, Christina Rossi RSU | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r22 · c15 · span 1296491–1296500 |
| 18 | Section 03, Kathryn Haviland OPTION | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t150 · r5 · c8 · span 1099007–1099016 |
| 19 | Section 03, Percy Carter RSU | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r33 · c15 · span 1355502–1355511 |
| 20 | Section 03, Michael Landsittel OPTION | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t150 · r8 · c8 · span 1113929–1113938 |
| 21 | Section 03, Fouad Namouni RSU | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t157 · r28 · c15 · span 1328644–1328653 |
| 22 | Section 03, Christina Rossi OPTION | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. Filing ↗machine: t150 · r11 · c8 · span 1128758–1128767 |
| 23 | Section 07, pay ratio | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “CEO Pay Ratio”. As printed: 35 : 1. Filing ↗ |
| 24 | Section 08, Lynn Seely | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “Director Compensation”. As printed: 606,190. Filing ↗machine: span 684459–684658 |
| 25 | Section 08, Mark Goldberg | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “Director Compensation”. As printed: 586,690. Filing ↗machine: span 677131–677330 |
| 26 | Section 08, Jeffrey W. Albers | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “Director Compensation”. As printed: 586,190. Filing ↗machine: span 659070–659269 |
| 27 | Section 08, Daniella Beckman | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “Director Compensation”. As printed: 574,690. Filing ↗machine: span 662662–662861 |
| 28 | Section 08, Lonnel Coats | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “Director Compensation”. As printed: 572,590. Filing ↗machine: span 669839–670038 |
| 29 | Section 08, Nicholas Lydon | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “Director Compensation”. As printed: 569,690. Filing ↗machine: span 680830–681029 |
| 30 | Section 08, Habib Dable | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “Director Compensation”. As printed: 564,990. Filing ↗machine: span 673434–673633 |
| 31 | Section 08, John Tsai | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “Director Compensation”. As printed: 549,690. Filing ↗machine: span 688086–688285 |
| 32 | Section 08, Alexis Borisy | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “Director Compensation”. As printed: 549,690. Filing ↗machine: span 666251–666450 |
| 33 | Section 08, Kathryn Haviland | DEF 14A | 2025-04-24 | 0001558370-25-005415 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 34 | Section 02, Christina Rossi 2025-05-05 | Form 4 | 2025-05-07 | 0001415889-25-012250 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Ariel Hurley 2025-05-05 | Form 4 | 2025-05-07 | 0001415889-25-012248 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Ariel Hurley 2025-05-05 | Form 4 | 2025-05-07 | 0001415889-25-012248 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Ariel Hurley 2025-05-05 | Form 4 | 2025-05-07 | 0001415889-25-012248 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Ariel Hurley 2025-05-05 | Form 4 | 2025-05-07 | 0001415889-25-012248 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Christina Rossi 2025-05-05 | Form 4 | 2025-05-07 | 0001415889-25-012250 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Christina Rossi 2025-05-05 | Form 4 | 2025-05-07 | 0001415889-25-012250 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Christina Rossi 2025-05-05 | Form 4 | 2025-05-07 | 0001415889-25-012250 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Christina Rossi 2025-05-19 | Form 4 | 2025-05-21 | 0001415889-25-013941 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Christina Rossi 2025-05-19 | Form 4 | 2025-05-21 | 0001415889-25-013941 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Christina Rossi 2025-05-19 | Form 4 | 2025-05-21 | 0001415889-25-013941 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Jeffrey W. Albers 2025-05-27 | Form 4 | 2025-05-29 | 0001415889-25-014862 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Jeffrey W. Albers 2025-05-27 | Form 4 | 2025-05-29 | 0001415889-25-014862 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Jeffrey W. Albers 2025-05-27 | Form 4 | 2025-05-29 | 0001415889-25-014862 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Jeffrey W. Albers 2025-05-27 | Form 4 | 2025-05-29 | 0001415889-25-014862 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Percy Carter 2025-06-03 | Form 4 | 2025-06-05 | 0001415889-25-015767 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Percy Carter 2025-06-03 | Form 4 | 2025-06-05 | 0001415889-25-015767 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Alexis Borisy 2025-06-18 | Form 4 | 2025-06-24 | 0001415889-25-018075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Mark Goldberg 2025-06-18 | Form 4 | 2025-06-24 | 0001415889-25-018084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Lonnel Coats 2025-06-18 | Form 4 | 2025-06-24 | 0001415889-25-018069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, John Tsai 2025-06-18 | Form 4 | 2025-06-24 | 0001415889-25-018065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Daniella Beckman 2025-06-18 | Form 4 | 2025-06-24 | 0001415889-25-018078 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Habib Dable 2025-06-18 | Form 4 | 2025-06-24 | 0001415889-25-018073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Jeffrey W. Albers 2025-06-18 | Form 4 | 2025-06-24 | 0001415889-25-018086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Lynn Seely 2025-06-18 | Form 4 | 2025-06-24 | 0001415889-25-018082 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Christina Rossi 2025-07-03 | Form 4 | 2025-07-08 | 0001415889-25-019507 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Percy Carter 2025-07-03 | Form 4 | 2025-07-08 | 0001415889-25-019506 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Michael Landsittel 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069396 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Michael Landsittel 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069396 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Fouad Namouni 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069383 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Mark Goldberg 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069384 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Mark Goldberg 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069384 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Mark Goldberg 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069384 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Mark Goldberg 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069384 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Mark Goldberg 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069384 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Alexis Borisy 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069385 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Christina Rossi 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069387 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Christina Rossi 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069387 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Lynn Seely 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069390 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Lynn Seely 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069390 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Lynn Seely 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069390 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Lynn Seely 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069390 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Lynn Seely 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069390 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Tracey L. McCain 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069381 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Jeffrey W. Albers 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069377 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Jeffrey W. Albers 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069377 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Debra Durso-Bumpus 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069379 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Jeffrey W. Albers 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069377 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Jeffrey W. Albers 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069377 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Daniella Beckman 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069382 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Debra Durso-Bumpus 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069379 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Daniella Beckman 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069382 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Kathryn Haviland 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069386 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Mark Goldberg 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069384 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Kathryn Haviland 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069386 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Christina Rossi 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069387 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Percy Carter 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069388 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Lynn Seely 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069390 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, L. Becker Hewes 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069391 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Lonnel Coats 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069392 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Ariel Hurley 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069394 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Habib Dable 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069395 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Michael Landsittel 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069396 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Michael Landsittel 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069396 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Kathryn Haviland 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069386 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Kathryn Haviland 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069386 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Kathryn Haviland 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069386 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Kathryn Haviland 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069386 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Percy Carter 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069388 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Percy Carter 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069388 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Lynn Seely 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069390 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, L. Becker Hewes 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069391 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, L. Becker Hewes 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069391 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, L. Becker Hewes 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069391 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Lonnel Coats 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069392 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Lonnel Coats 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069392 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Ariel Hurley 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069394 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Ariel Hurley 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069394 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Ariel Hurley 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069394 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Ariel Hurley 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069394 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Ariel Hurley 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069394 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Ariel Hurley 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069394 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Habib Dable 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069395 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Michael Landsittel 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069396 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, Michael Landsittel 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069396 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Ariel Hurley 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069394 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Philina Lee 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069378 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Debra Durso-Bumpus 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069379 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Debra Durso-Bumpus 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069379 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Debra Durso-Bumpus 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069379 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, Debra Durso-Bumpus 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069379 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, Tracey L. McCain 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069381 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, Tracey L. McCain 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069381 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, Tracey L. McCain 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069381 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, Tracey L. McCain 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069381 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, Tracey L. McCain 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069381 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, Tracey L. McCain 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069381 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, Daniella Beckman 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069382 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, Mark Goldberg 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069384 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 02, L. Becker Hewes 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069391 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 134 | Section 02, Michael Landsittel 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069396 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 135 | Section 02, L. Becker Hewes 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069391 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 136 | Section 02, Ariel Hurley 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069394 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 137 | Section 02, Ariel Hurley 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069394 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 138 | Section 02, Ariel Hurley 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069394 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 139 | Section 02, Habib Dable 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069395 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 140 | Section 02, Habib Dable 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069395 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 141 | Section 02, Michael Landsittel 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069396 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 142 | Section 02, Fouad Namouni 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069383 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 143 | Section 02, Fouad Namouni 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069383 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 144 | Section 02, Mark Goldberg 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069384 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 145 | Section 02, Mark Goldberg 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069384 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 146 | Section 02, Mark Goldberg 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069384 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 147 | Section 02, Alexis Borisy 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069385 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 148 | Section 02, Alexis Borisy 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069385 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 149 | Section 02, Alexis Borisy 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069385 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 150 | Section 02, Alexis Borisy 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069385 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 151 | Section 02, Alexis Borisy 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069385 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 152 | Section 02, Alexis Borisy 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069385 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 153 | Section 02, Kathryn Haviland 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069386 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 154 | Section 02, Kathryn Haviland 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069386 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 155 | Section 02, Kathryn Haviland 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069386 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 156 | Section 02, Kathryn Haviland 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069386 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 157 | Section 02, Kathryn Haviland 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069386 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 158 | Section 02, Kathryn Haviland 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069386 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 159 | Section 02, Christina Rossi 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069387 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 160 | Section 02, Christina Rossi 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069387 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 161 | Section 02, Christina Rossi 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069387 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 162 | Section 02, Percy Carter 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069388 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 163 | Section 02, Percy Carter 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069388 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 164 | Section 02, Percy Carter 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069388 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 165 | Section 02, Lynn Seely 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069390 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 166 | Section 02, Lynn Seely 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069390 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 167 | Section 02, Lynn Seely 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069390 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 168 | Section 02, Lynn Seely 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069390 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 169 | Section 02, L. Becker Hewes 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069391 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 170 | Section 02, L. Becker Hewes 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069391 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 171 | Section 02, L. Becker Hewes 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069391 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 172 | Section 02, Lonnel Coats 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069392 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 173 | Section 02, Jeffrey W. Albers 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069377 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 174 | Section 02, Jeffrey W. Albers 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069377 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 175 | Section 02, Jeffrey W. Albers 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069377 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 176 | Section 02, Philina Lee 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069378 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 177 | Section 02, Philina Lee 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069378 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 178 | Section 02, Philina Lee 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069378 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 179 | Section 02, Philina Lee 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069378 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 180 | Section 02, Debra Durso-Bumpus 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069379 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 181 | Section 02, Debra Durso-Bumpus 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069379 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 182 | Section 02, Debra Durso-Bumpus 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069379 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 183 | Section 02, Debra Durso-Bumpus 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069379 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 184 | Section 02, Debra Durso-Bumpus 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069379 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 185 | Section 02, Tracey L. McCain 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069381 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 186 | Section 02, Tracey L. McCain 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069381 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 187 | Section 02, Tracey L. McCain 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069381 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 188 | Section 02, Tracey L. McCain 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069381 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 189 | Section 02, Tracey L. McCain 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069381 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 190 | Section 02, Fouad Namouni 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069383 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 191 | Section 02, Christina Rossi 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069387 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 192 | Section 02, Christina Rossi 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069387 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 193 | Section 02, Christina Rossi 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069387 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 194 | Section 02, Christina Rossi 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069387 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 195 | Section 02, Lonnel Coats 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069392 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 196 | Section 02, Lonnel Coats 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069392 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 197 | Section 02, Lonnel Coats 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069392 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 198 | Section 02, Lonnel Coats 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069392 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 199 | Section 02, Lonnel Coats 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069392 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 200 | Section 02, Percy Carter 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069388 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 201 | Section 02, Percy Carter 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069388 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 202 | Section 02, John Tsai 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069393 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 203 | Section 02, John Tsai 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069393 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 204 | Section 02, John Tsai 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069393 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 205 | Section 02, John Tsai 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069393 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 206 | Section 02, Daniella Beckman 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069382 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 207 | Section 02, Daniella Beckman 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069382 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 208 | Section 02, Daniella Beckman 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069382 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 209 | Section 02, Habib Dable 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069395 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 210 | Section 02, Fouad Namouni 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069383 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 211 | Section 02, Fouad Namouni 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069383 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 212 | Section 02, Fouad Namouni 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069383 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 213 | Section 02, Fouad Namouni 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069383 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 214 | Section 02, Fouad Namouni 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069383 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 215 | Section 02, Alexis Borisy 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069385 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 216 | Section 02, Alexis Borisy 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069385 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 217 | Section 02, Michael Landsittel 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069396 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 218 | Section 02, Michael Landsittel 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069396 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 219 | Section 02, Michael Landsittel 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069396 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 220 | Section 02, Jeffrey W. Albers 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069377 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 221 | Section 02, Jeffrey W. Albers 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069377 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 222 | Section 02, Jeffrey W. Albers 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069377 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 223 | Section 02, John Tsai 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069393 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 224 | Section 02, Michael Landsittel 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069396 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 225 | Section 02, Lonnel Coats 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069392 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 226 | Section 02, Lynn Seely 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069390 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 227 | Section 02, Philina Lee 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069378 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 228 | Section 02, Philina Lee 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069378 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 229 | Section 02, Ariel Hurley 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069394 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 230 | Section 02, Philina Lee 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069378 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 231 | Section 02, Kathryn Haviland 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069386 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 232 | Section 02, Christina Rossi 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069387 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 233 | Section 02, Tracey L. McCain 2025-07-17 | Form 4 | 2025-07-21 | 0001104659-25-069381 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 234 | Section 06, 2025 vote | Form 8-K | 2025-06-20 | 0001558370-25-008742 | Item 5.07 · say-on-pay result. As reported: 95.93% (votes for as printed: 57,714,069). Filing ↗ |
| 235 | Section 06, 2024 vote | Form 8-K | 2024-06-14 | 0001104659-24-071734 | Item 5.07 · say-on-pay result. As reported: 97.69% (votes for as printed: 56,844,879). Filing ↗ |
| 236 | Section 06, 2023 vote | Form 8-K | 2023-06-27 | 0001104659-23-075235 | Item 5.07 · say-on-pay result. As reported: 98.17% (votes for as printed: 54,299,704). Filing ↗ |
| 237 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 238 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 239 | Section 09b board cost (computed) | Computed | — | — | Cash 628,200 + equity 2,141,694 + all other 35,000 = 2,804,894, summed across the director compensation table rows.machine: formula: Σ = 2,804,894 |
| 240 | Exelixis, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0000939767-26-000046 | CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526 |
| 241 | PTC Therapeutic, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045528 | CEO total compensation as printed in PTC Therapeutic's own proxy. As printed: 23,266,326. Filing ↗ |
| 242 | Halozyme Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-03-23 | 0001159036-26-000041 | CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292 |
| 243 | United Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001082554-26-000009 | CEO total compensation as printed in United Therapeutics, Inc.'s own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736 |
| 244 | Blueprint Medicines (subject), Section 10b CEO total | DEF 14A | 2025-04-24 | 0001558370-25-005415 | CEO total compensation as printed in Blueprint Medicines's own proxy. As printed: 13,477,004. Filing ↗machine: span 1101152–1101162 |
| 245 | Neurocrine Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0000914475-26-000015 | CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957 |
| 246 | Ionis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016388 | CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. Filing ↗ |
| 247 | BioCryst Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001628280-26-026822 | CEO total compensation as printed in BioCryst Pharmaceuticals, Inc.'s own proxy. As printed: 12,951,082. Filing ↗machine: span 512256–512266 |
| 248 | Mirati Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2023-04-06 | 0001628280-23-011004 | CEO total compensation as printed in Mirati Therapeutics, Inc.'s own proxy. As printed: 11,937,371. Filing ↗machine: r2 · c45 · span 540567–540577 |
| 249 | Ultragenyx Pharmaceutical Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0001308179-26-000174 | CEO total compensation as printed in Ultragenyx Pharmaceutical Inc.'s own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007 |
| 250 | Apellis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2025-04-23 | 0000950170-25-056966 | CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565 |
| 251 | Amicus Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-24 | 0001140361-25-015479 | CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136 |
| 252 | ACADIA Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in ACADIA Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. Filing ↗ |
| 253 | Alkermes, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001193125-26-143977 | CEO total compensation as printed in Alkermes, Inc.'s own proxy. As printed: 7,915,081. Filing ↗machine: r3 · c33 · span 2508258–2508267 |
| 254 | Sarepta Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177247 | CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. Filing ↗machine: span 1454395–1454404 |
| 255 | CRISPR Therapeutics AG, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001193125-26-165158 | CEO total compensation as printed in CRISPR Therapeutics AG's own proxy. As printed: 7,678,477. Filing ↗machine: r2 · c25 · span 821649–821658 |
| 256 | Deciphera Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2024-04-25 | 0001654151-24-000012 | CEO total compensation as printed in Deciphera Pharmaceuticals, Inc.'s own proxy. As printed: 6,010,712. Filing ↗machine: span 605886–605895 |
| 257 | Agios Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177086 | CEO total compensation as printed in Agios Pharmaceuticals, Inc.'s own proxy. As printed: 5,370,389. Filing ↗machine: r2 · c31 · span 613185–613194 |
| 258 | Section 10a, Apellis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0000950170-25-056966 | Apellis Pharmaceuticals, Inc. names Blueprint Medicines in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 259 | Section 10a, Deciphera Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001654151-24-000012 | Deciphera Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Blueprint Medicines. Filing ↗ |
| 260 | Section 10a, Mirati Therapeutics, Inc. reciprocity | DEF 14A | — | 0001628280-23-011004 | Mirati Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Blueprint Medicines. Filing ↗ |
| 261 | Section 10a, United Therapeutics, Inc. reciprocity | DEF 14A | — | 0001082554-26-000009 | United Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Blueprint Medicines. Filing ↗ |
| 262 | Section 10a, PTC Therapeutic reciprocity | DEF 14A | — | 0001104659-26-045528 | PTC Therapeutic names Blueprint Medicines in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 263 | Section 10a, Sarepta Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-177247 | Sarepta Therapeutics, Inc. names Blueprint Medicines in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 264 | Section 10a, Ultragenyx Pharmaceutical Inc. reciprocity | DEF 14A | — | 0001308179-26-000174 | Ultragenyx Pharmaceutical Inc. names Blueprint Medicines in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 265 | Section 10a, Halozyme Therapeutics, Inc. reciprocity | DEF 14A | — | 0001159036-26-000041 | Halozyme Therapeutics, Inc. names Blueprint Medicines in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 266 | Section 10a, ACADIA Pharmaceuticals Inc. reciprocity | DEF 14A | — | 0001193125-26-174163 | ACADIA Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Blueprint Medicines. Filing ↗ |
| 267 | Section 10a, BioCryst Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-26-026822 | BioCryst Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Blueprint Medicines. Filing ↗ |
| 268 | Section 10a, Neurocrine Biosciences, Inc. reciprocity | DEF 14A | — | 0000914475-26-000015 | Neurocrine Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Blueprint Medicines. Filing ↗ |
| 269 | Section 10a, Amicus Therapeutics, Inc. reciprocity | DEF 14A | — | 0001140361-25-015479 | Amicus Therapeutics, Inc. names Blueprint Medicines in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 270 | Section 10a, Agios Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001193125-26-177086 | Agios Pharmaceuticals, Inc. names Blueprint Medicines in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 271 | Section 10a, Ionis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001140361-26-016388 | Ionis Pharmaceuticals, Inc. names Blueprint Medicines in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 272 | Section 10a, CRISPR Therapeutics AG reciprocity | DEF 14A | — | 0001193125-26-165158 | CRISPR Therapeutics AG names Blueprint Medicines in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 273 | Section 10a, Exelixis, Inc. reciprocity | DEF 14A | — | 0000939767-26-000046 | Exelixis, Inc.'s most recent proxy was read; its disclosed peer group does not include Blueprint Medicines. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.